drugset / Trial / NCT03412513

Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease

NCT03412513

Phase 4 Unknown 144 enrolled Seoul National University Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to see the study drug, Mirabegron, is safe and effective in treating symptoms of Overactive Bladder in patients with Parkinson's disease.

Timeline

Start
2017-07-17
Primary completion
2018-07-16
Completion
2018-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mirabegron Other / unclassified 50 mg Oral